July 30, 2019 / 8:09 PM / 21 days ago

Gilead quarterly profit rises 3.5%

July 30 (Reuters) - Gilead Sciences Inc reported a 3.5% rise in quarterly profit on Tuesday, as higher sales of its HIV drugs cushioned sluggish demand for its flagship hepatitis C treatments.

Net income attributable to Gilead rose to $1.88 billion, or $1.47 per share, in the second quarter ended June 30, from $1.82 billion, or $1.39 per share, a year earlier.

Total revenue rose to $5.69 billion from $5.65 billion. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below